$InterCure (INCR.US)$ NEWS InterCure Announces FY2023 Result...
NEWS
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
InterCure achieved annual revenue of NIS 356 million and adjusted EBITDA of NIS 61 million, representing 17% of revenues.
The company maintained profitability for the fourteenth and fifteenth consecutive quarters despite challenges.
InterCure continues to expand its product portfolio and dedicated medical cannabis pharmacy chain.
The company is entitled to full compensation for damages caused by the terrorist attack and war in Gaza, receiving tens of millions of NIS as advance payments.
InterCure plans to launch its first products in Germany and expects sequential quarterly growth in 2024.
The company maintained profitability for the fourteenth and fifteenth consecutive quarters despite challenges.
InterCure continues to expand its product portfolio and dedicated medical cannabis pharmacy chain.
The company is entitled to full compensation for damages caused by the terrorist attack and war in Gaza, receiving tens of millions of NIS as advance payments.
InterCure plans to launch its first products in Germany and expects sequential quarterly growth in 2024.
Revenues in H2 2023 were affected by damages from the terrorist attack and war in Gaza.
The company's Southern Facility was in access due to the war situation, impacting operations.
The company's Southern Facility was in access due to the war situation, impacting operations.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1666Followers
93Following
13KVisitors
Follow